​

Caris Life Sciences (CAI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CAI Stock Forecast

Caris Life Sciences (CAI) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $28.60, with a high of $38.00 and a low of $21.00. This represents a 79.42% increase from the last price of $15.94.

CAI Stock Rating

Caris Life Sciences stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

CAI Price Target Upside V Benchmarks

TypeNameUpside
StockCaris Life Sciences79.42%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts239
Avg Price Target$27.00$25.00$30.44
Last Closing Price$15.94$15.94$15.94
Upside/Downside69.39%56.84%90.97%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 261102--13
Apr, 26191--11
Mar, 26181--10
Feb, 26171--9
Jan, 26171--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 08, 2026Catherine Ramsey SchulteRobert W. Baird$22.00$15.9737.76%38.02%
May 08, 2026Mark MassaroBTIG$32.00$19.8461.29%100.75%
Apr 10, 2026Piper Sandler$21.00$17.8917.38%31.74%
Feb 17, 2026Robert W. Baird$26.00$20.6226.09%63.11%
Jan 05, 2026Evercore ISI$38.00$26.6842.43%138.39%
Dec 22, 2025Kyle MiksonCanaccord Genuity$30.00$27.947.37%88.21%
Dec 02, 2025Canaccord Genuity$28.00$26.057.49%75.66%
Aug 13, 2025Mark MassaroBTIG$45.00$34.7829.38%182.31%
Jul 13, 2025Subbu NambiGuggenheim$32.00$26.5120.71%100.75%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 08, 2026New StreetPerforminitialise
May 08, 2026BTIGBuyBuyhold
Apr 10, 2026Piper SandlerNeutralinitialise
Aug 13, 2025BTIGBuyBuyhold
Jul 14, 2025Wolfe ResearchOutperforminitialise
Jul 14, 2025CitigroupBuyinitialise
Jul 14, 2025Cowen & Co.Buyinitialise
Jul 13, 2025GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast$5.71$-10.43-$0.21$0.66
High Forecast$6.84$-10.43-$0.39$0.85
Low Forecast$4.58$-10.43-$0.03$0.29
Surprise %-----

Revenue Forecast

$300M $480M $660M $840M $1B $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast$421.94M$452.50M$330.09M$939.25M$1.16B
High Forecast$506.33M$452.50M$330.09M$939.25M$1.16B
Low Forecast$337.55M$452.50M$330.09M$939.25M$1.16B
Surprise %-----

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast$123.78M$-187.27M-$3.77M$10.23M
High Forecast$148.53M$-187.27M-$7.00M$15.26M
Low Forecast$99.02M$-187.27M-$538.47K$5.21M
Surprise %-----

CAI Forecast FAQ

Is Caris Life Sciences stock a buy?

Caris Life Sciences stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Caris Life Sciences is a favorable investment for most analysts.

What is Caris Life Sciences's price target?

Caris Life Sciences's price target, set by 7 Wall Street analysts, averages $28.6 over the next 12 months. The price target range spans from $21 at the low end to $38 at the high end, suggesting a potential 79.42% change from the previous closing price of $15.94.

How does Caris Life Sciences stock forecast compare to its benchmarks?

Caris Life Sciences's stock forecast shows a 79.42% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Caris Life Sciences over the past three months?

  • May 2026: 7.69% Strong Buy, 76.92% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Caris Life Sciences’s EPS forecast?

Caris Life Sciences's average annual EPS forecast for its fiscal year ending in December 2023 is $5.71, marking a 0% decrease from the reported - in 2022. Estimates for the following years are $-10.43 in 2024, $0 in 2025, $0.21 in 2026, and $0.66 in 2027.

What is Caris Life Sciences’s revenue forecast?

Caris Life Sciences's average annual revenue forecast for its fiscal year ending in December 2023 is $421.94M, reflecting a 0% decrease from the reported - in 2022. The forecast for 2024 is $452.5M, followed by $330.09M for 2025, $939.25M for 2026, and $1.16B for 2027.

What is Caris Life Sciences’s net income forecast?

Caris Life Sciences's net income forecast for the fiscal year ending in December 2023 stands at $123.78M, representing a 0% decrease from the reported - in 2022. Projections indicate $-187M in 2024, $0 in 2025, $3.77M in 2026, and $10.23M in 2027.